A phase 2 clinical trial of nab-Paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma

Cancer

Volumn 116, Issue 1, 2010, Pages 155-163

  Hersh, Evan M ^a   O'Day, Steven J ^b   Ribas, Antoni ^c   Samlowski, Wolfram E ^d   Gordon, Michael S ^e   Shechter, Deganit E ^f   Clawson, Alicia A ^f   Gonzalez, Rene ^g  

^a UNIVERSITY OF ARIZONA   (United States)

^b Angeles Clinic and Research Institute   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NEVADA CANCER INSTITUTE   (United States)

^e Premiere Oncology of Arizona   (United States)

^f Abraxis BioScience   (United States)

^g UNIVERSITY OF COLORADO   (United States)

Author keywords

ABI 007 (Abraxane); Melanoma; nab paclitaxel; Overall survival

Indexed keywords

DACARBAZINE; PACLITAXEL;

ABDOMEN; ADULT; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD CELL COUNT; BLOOD CHEMISTRY; BLOOD TOXICITY; BONE MARROW TOXICITY; BRAIN; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED STUDY; DESQUAMATION; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPONATREMIA; LABORATORY TEST; LEUKOPENIA; LIVER; LUNG; LYMPH NODE; MALE; MELANOMA; METASTASIS; MOTOR NEUROPATHY; MUCOSA; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PAIN; PERITONEUM; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROBABILITY; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; SENSORY NEUROPATHY; SKIN; SOFT TISSUE; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; TUMOR LOCALIZATION; UVEA;

AGED; ALBUMINS; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MELANOMA; NEOPLASM METASTASIS; PACLITAXEL; SKIN NEOPLASMS;

EID: 74549221384     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24720     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
2. Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg. 1995;181:193-201.
3. Fletcher WS, Pommier RF, Lum S, Wilmarth TJ. Surgical treatment of metastatic melanoma. Am J Surg. 1998;175:413-417.
4. Li Y, McClay EF. Systemic chemotherapy for the treatment of metastatic melanoma. Semin Oncol. 2002;29:413-426.
5. Bedikian AY, Millward M, Pehamberger H, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol. 2006;24:4738-4745.
6. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18:158-166.
7. Tarhini AA, Kirkwood JM, Gooding WE, Cai C, Agarwala SS. Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J Clin Oncol. 2007;25:3802-3807.
8. Bedikian AY, Plager C, Papadopoulos N, Eton O, Ellerhorst J, Smith T. Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma. Melanoma Res. 2004;14:63-66.
9. Einzig AI, Hochster H, Wiernik PH, et al. A phase II study of taxol in patients with malignant melanoma. Invest New Drugs. 1991;9:59-64.
10. Legha SS, Ring S, Papadopoulos N, Raber M, Benjamin RS. A phase II trial of taxol in metastatic melanoma. Cancer. 1990;65:2478-2481.
11. Walker L, Schalch H, King DM, et al. Phase II trial of weekly paclitaxel in patients with advanced melanoma. Melanoma Res. 2005;15:453-459.
12. Aamdal S, Wolff I, Kaplan S, et al. Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group. Eur J Cancer. 1994;30A:1061-1064.
13. Bedikian AY, Weiss GR, Legha SS, et al. Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J Clin Oncol. 1995;13:2895-2899.
14. Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother. 2006;7:1041-1053.
15. Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel. Clin Cancer Res. 2006;12:1317-1324.
16. Ibrahim NK, Desai N, Legha S, et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res. 2002;8:1038-1044.
17. Nyman DW, Campbell KJ, Hersh E, et al. A phase I and pharmacokinetics trial of ABI-007, a novel formulation of paclitaxel stabilized with human serum albumin, administered weekly for 3 doses every 4 weeks in patients with advanced non-hematologic malignancies. J Clin Oncol. 2005;23:7785-7793.
18. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794-7803.
19. Gradishar W, Krasnojon D, Cheporov S, et al. Randomized comparison of weekly or every-3-week (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (pts) with metastatic breast cancer (MBC). 2007 ASCO Annual Meeting Proceedings pt I. J Clin Oncol. 2007;25(18 suppl):1032.
20. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216.
21. Korn EL, Liu PY, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008;26:517-518.
22. Simionescu M, Gafencu A, Antohe F. Transcytosis of plasma macromolecules in endothelial cells: a cell biological survey. Microsc Res Tech. 2002;57:269-288.
23. John TA, Vogel SM, Tiruppathi C, Malik AB, Minshall RD. Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am J Physiol Lung Cell Mol Physiol. 2003;284:L187-L196.
24. Trieu V, Hwang J, Desai N. Nanoparticle albumin-bound (nab) technology may enhance antitumor activity via targeting of SPARC protein [abstract]. Presented at: New Targets and Delivery Systems for Cancer Diagnosis and Treatment, March 5-7, 2007, San Diego, California. Abstract 53.
25. Porter PL, Sage EH, Lane TF, Funk SE, Gown AM. Distribution of SPARC in normal and neoplastic human tissue. J Histochem Cytochem. 1995;43:791-800.
26. Massi D, Franchi A, Borgognoni L, Reali UM, Santucci M. Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum Pathol. 1999;30:339-344.
27. Framson PE, Sage EH. SPARC and tumor growth: where the seed meets the soil? J Cell Biochem. 2004;92:679-690.
28. Sparreboom A, Scripture CD, Trieu V, et al. Comparative preclinical and clinical pharmacokinetics of a Cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res. 2005;11:4136-4143.
29. Yeh TK, Lu Z, Wientjes MG, Au JL. Formulating paclitaxel in nanoparticles alters its disposition. Pharm Res. 2005;22:867-874.
30. Agarwala SS, Keilholz U, Hogg D, et al. Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma. 2007 ASCO Annual Meeting Proceedings pt I. J Clin Oncol. 2007;25(18 suppl):8510.